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Students’ Corner
Short Communication
Effect of percutaneous mitral vavuloplasty on pregnant mother and
foetus — a tertiary care hospital experience from a developing country
Syed Haider Imam,1 Abbas Haider Zaidi,2 Sana Shoukat,3 Sajid Hamid Dhakam4
Medical College,1,2 Section of Cardiology, Department of Medicine,3,4 Aga Khan University Hospital, Karachi, Pakistan.

Abstract
This study evaluated the short and long-term
consequences of Percutaneous Mitral Valvuloplasty (PMV)
in pregnant patients and their offspring, in a tertiary care
setting, Karachi, Pakistan.
The hospital database was used to retrieve all patients
who underwent PMV during pregnancy in the period 19982007. The follow up data of the patients and the born children
were obtained from the hospital records and also by
contacting the patients via phone.
Six patients underwent PMV but follow-up was
available for 5 patients only. All 5 patients were admitted due
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to severe mitral stenosis with symptoms of dyspnea and
palpitation. Mean age was 27 ± 5.3 years with a mean
gestational age at the time of procedure of 22.20 ± 1.6 weeks.
The mean valve area increased from 0.94 ± 0.22 cm2 preoperatively to 1.62 ± 0.50 cm2 post-operatively. The ejection
fraction changed from a mean of 50 ± 11.7 % to 56 ± 2.2 %.
There were no maternal deaths, abortions or stillbirths.
Developmental milestones were achieved at the appropriate
ages in all babies.
PMV appears to be a safe and effective intervention
for patients with severe MS during pregnancy.
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Introduction

Methods

Mitral stenosis (MS) is the most common valvular
lesion seen in pregnancy worldwide and is often the most
poorly tolerated.1 Problems associated with mitral stenosis in
pregnancy are due to further narrowing of mitral valve and
the haemodynamic change that take place.2 Pregnancy is a
burden even in normal patients by causing an increase of 30%
to 50% in intravascular volume. This can lead to an increase
in transmitral gradient and left atrial pressure and also cause
flash pulmonary oedema.3 Maternal mortality for patients
with MS are significantly higher (6.8%) for those who are
New York Heart Association (NYHA) class 3 and 4 than
patients who are NYHA class 1 and 2 (0.4%), particularly
during labour and delivery.4

The Aga Khan University Hospital database was used
to retrieve all patients who underwent PMV during
pregnancy between the period of 1998 and 2007. The follow
up data of the patients and the born children were obtained
from the medical records available and follow up was done
by contacting the patients via phone.

These symptoms usually become apparent by the
20th week of pregnancy and can be aggravated even further
at the time of labour and delivery. Maternal death is rare
when careful attention is paid to the management of
congestive heart failure.5 Percutaneous Mitral valvuloplasty
(PMV) is indicated in symptomatic patients with mitral
stenosis.2,6 For pregnant patients, however, medical
management is recommended and PMV only if the patient
fails medical management during pregnancy with repetitive
or persistent heart failure. There exists more than ten years
experience with PMV in pregnant patients in the literature.7
However, the safety and efficacy of this procedure has not
been clearly established for pregnant patients. Surgical
commissurotomy is indeed effective but with higher
maternal mortality rate (1.7%-3.1%) and infant mortality
rate ranging from 5% to 33%.4,8
In our part of the world, MS is the major lesion found
during pregnancy, the main cause of which is rheumatic heart
disease.9,10 This is attributed to poor socio-economic status,
overcrowded living conditions and poor access to medical
care.9 The data from Pakistan is scarce, and to our knowledge
few studies have been done regarding the effects of PMV on
pregnancy outcome and the newborn child.
The objective of this study was to evaluate short and
long-term consequences of PMV, in a tertiary care setting,

All pregnant women presenting with mitral valve
disease (Mitral stenosis and regurgitation) and undergoing
PMV from 1998-2007 were included in this study. Patients who
were not available for follow-up were excluded from the study.
Patients were followed up to document residual
symptoms of mitral valve disease (NYHA class), procedurerelated complications, need for surgical intervention postPMV. Possible maternal confounding factors such as comorbidities were also documented. Pregnancy outcomes such
as weight of the new-born, CTG (cardiotocography), mode
and complications of delivery, post-natal well-being as well
as developmental milestones or delays were also recorded.
A baseline echocardiogram was performed in all
patients. PMV was performed after taking an informed
written consent as per standard protocol. Antibiotic
prophylaxis was initiated in all patients thereafter. The
procedure was performed under local anaesthesia and lead
abdominal protection was used in all patients.
Summary statistics are presented using mean and
standard deviation (mean ± SD) for continuous variables and
using frequencies for categorical variables.

Results
From 1998 to 2007, a total of 56 patients underwent
PMV at the Aga Khan University Hospital, Karachi, Pakistan.
Out of the 39 females, 6 were pregnant and had mitral stenosis
for which they had mitral valvuloplasty done. Follow-up for 5
patients was available as there was a loss to follow up of 1
patient. Average follow-up for this study was 4.5 years
conducted in March 2009. These five women were admitted
due to severe mitral stenosis with common presentation of
dyspnoea and palpitations. Other symptoms included

Table-1: Patient profiles.
No.

Weeks of
Para/ Mode of
Weeks of gestation
Child’s age at the
gestation at delivery gravida delivery at time of surgery (wks) time of research

1
2
3
4

31+
28
32+
37

G1 P0
G1 P0
G1P0
G8 P3 +5

NVD
LSCS
NVD
LSCS

26
22
21
22

3 y 6m
3y
8m
7y1m

5

37

G2P1+0

LSCS

20

10 m

Problems during Child’s weight at time Developmental
pregnancy to fetus
of delivery (kg)
defects after birth
none
Suboptimal CTG+IUGR
none
Suboptimal CTG+
IUGR at 34 weeks
None

1.8
1.4
2.0g
2.5 kg

none
none
none
none

2.6 kg

none

CTG: Cardiotocography. NVD: Normal Vaginal Delivery. LSCS: Lower Segment Caesarian Section. IUGR: Intrauterine Growth Retardation.
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Table-2: Pre and post-procedure echocardiogram.
Patient Pre/Post
1
1
2
2
3
3
4
4
5
5

PRE
POST
PRE
POST
PRE
POST
PRE
POST
PRE
POST

EF* /% MPG*/mmhg
50
55
55
60
60
55
30
55
55
55

08
03
20
13
23
11
07
04
34
25

MVA*/cm2 Pul.HTN*
0.9
2.3
0.6
2.1
1.5
1.7
0.8
0.9
0.9
1.1

Severe
Severe
Mild
Severe
moderate
severe
Moderate

Pasp

LA clot

MR

Other

70
70
55
40
135
90

No
No
Thrombus at L.A appendage
No
No
No
No
No
No
No

moderate
Mild to moderate
No MR
Moderate
mild to moderate
mild

ASD* 11mm L'R shunt
ASD* 11mm L'R shunt
-

mild
Trace to mild
None

-

*EF = ejection fraction; MPG = mean pressure gradient; MVA=mitral valve area; PUL.HTN =pulmonary hypertension; ASD = atrial septal defect; Pasp= pulmonary artery systolic
pressure.

Table-3: Post-procedure Change in baseline characteristics.
Patient
1
2
3
4
5

Age

NYHA

Worsening of symptoms

Stroke

AF

20
24
35
33
25

1-2
1-2
1-2
1-2
1-2

N
N
N
N
N

N
N
N
N
N

N
N
N
Y(post-op)
N

exertional chest pain, productive cough and atrial fibrillation.
One of the patients also had a history of atrial septal defect.
The mean age of patients was 27.0 ± 5.3 years, with a mean
gestational age at the time of procedure of 22.2 ± 1.6 weeks.

months. All babies were normal at birth and maintained
normal growth and development without any thyroid disease
or malignancy. Developmental milestones were achieved at
the appropriate ages in all babies.

Follow-up of the infant after birth was also available
for all five patients and is presented in Table-1.

Discussion

There was a noteworthy increase in valve area and
decrease in mean pressure gradient (MPG) after PMV
(Table-2). The mean valve area increased from 0.94 ± 0.22
cm2 pre-operatively to 1.62 ± 0.50 cm2 post-operatively.
The ejection fraction changed mildly from a mean of 50 ±
11.7% to 56 ± 2.2%.
Only one patient had atrial fibrillation and
hypertension post-procedure. Most patients did not show any
recurrence of symptoms or any problem related to previously
diagnosed mitral stenosis after the valvuloplasty and there
was improvement in NYHA class of heart failure in all
patients (Table-3). One patient had to undergo mitral valve
replacement after one year due to persistent symptoms (chest
pain and dyspnoea). Two patients had infant birth through
normal vaginal delivery while the other three had them
through Caesarean section. There were no maternal deaths,
abortion or stillbirths seen. Two patients delivered
prematurely and Intrauterine growth retardation with suboptimal Cardiotocography (CTG) were seen in their foetuses
(50%). The infants were born with a mean weight of 2.1 ±
0.50 kg. These infants were followed up till July 2007 over a
period of average 158 weeks. Their mean age was 36.2 ± 5.9
Vol. 61, No. 11, November 2011

PMV has largely replaced surgical valvulotomy or
MVR in MS in the absence of contraindications11 and newer
approaches to valve replacement are being carried out.12 The
aim of PMV during pregnancy is to relieve symptoms and
prevent adverse effects on foetal well being due to the
haemodynamic compromise. In Pakistan where antenatal
diagnosis of MS is frequently missed,13 this becomes a very
important tool to help mother and baby during pregnancy but
the adverse effects and potential complications associated
with the procedure has always been a concern to the health of
mother and infant alike, especially due to the use of contrast
and radiation during the procedure.14,15 This radiation can
have potential teratogenic effects. The nature and severity of
the harmful effects to the embryo or foetus associated with
radiation are related to the gestational age at which the
exposure occurs.16 Fatal effects include organ malformation,
severe mental retardation and malignancy, especially
leukaemia.17,18
Our findings are consistent with other data in which
the major symptoms, gestational age at the time of procedure,
outcomes of pregnancy and long-term follow up closely
correlate with our patients.7,19,20 However, the percentage of
pre-term delivery was higher in our series, which is likely
1159

because of the small sample size and were not seen in other
studies.21 No abnormalities in growth or development were
seen. Two cases of premature delivery were seen leading to a
procedure. This caused us to speculate that this might be
related to the effects of either mitral stenosis during
pregnancy and its effects on the foetus or due to mitral
valvuloplasty and the radiation being used.22-24 However,
there is no reported case of abortion or still birth in our study.
Although still birth and abortion rates are very low, they were
present in other studies.19,24 The functional class improved
dramatically to NYHA class 1 or 2 which is again consistent
with other studies in literature.7,19,20
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et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for
the management of patients with valvular heart disease: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 1998 Guidelines for the
Management of Patients With Valvular Heart Disease): endorsed by the Society
of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography
and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:
e523-661.

7.

Esteves CA, Munoz JS, Braga S, Andrade J, Meneghelo Z, Gomes N, et al.
Immediate and long-term follow-up of percutaneous balloon mitral
valvuloplasty in pregnant patients with rheumatic mitral stenosis. Am J Cardiol
2006; 98: 812-6.

8.
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Opin Cardiol 2005; 20: 100-6.

12.

Feldman T, Herrmann HC, St Goar F. Percutaneous treatment of valvular heart
disease: catheter-based aortic valve replacement and mitral valve repair
therapies. Am J Geriatr Cardiol 2006; 15: 291-301.

13.

Bhutta SZ, Aziz S, Korejo R. Pregnancy following cardiac surgery. J Pak Med
Assoc 2003; 53: 407-13.

14.

Safian RD, Berman AD, Sachs B, Diver DJ, Come PC, Baim DS, et al.
Percutaneous balloon mitral valvuloplasty in a pregnant woman with mitral
stenosis. Cathet Cardiovasc Diagn 1988; 15: 103-8.

15.

Cheng TO. Long-term results of percutaneous balloon mitral valvuloplasty
using the Inoue balloon catheter technique. Circulation 2000; 101: E91.

16.

Mangione JA, Lourenco RM, dos Santos ES, Shigueyuki A, Mauro MF,
Cristovao SA, et al. Long-term follow-up of pregnant women after
percutaneous mitral valvuloplasty. Catheter Cardiovasc Interv 2000; 50: 413-7.

17.

Fattibene P, Mazzei F, Nuccetelli C, Risica S. Prenatal exposure to ionizing
radiation: sources, effects and regulatory aspects. Acta Paediatr 1999; 88: 693702.

Conclusion

18.

Balter S. Radiation safety in the cardiac catheterization laboratory: operational
radiation safety. Catheter Cardiovasc Interv 1999; 47: 347-53.

PMV appears to be a safe and effective intervention
for patients with severe MS during pregnancy. Larger
definitive studies, however, need to be executed especially in
our population.

19.

Sivadasanpillai H, Srinivasan A, Sivasubramoniam S, Mahadevan KK, Kumar
A, Titus T, et al. Long-term outcome of patients undergoing balloon mitral
valvotomy in pregnancy. Am J Cardiol 2005; 95: 1504-6.

20.

Salome N, Dias CC, Ribeiro J, Goncalves M, Fonseca C, Ribeiro VG. Balloon
mitral valvuloplasty during pregnancy - our experience. Rev Port Cardiol 2002;
21: 1437-44.

21.

Routray SN, Mishra TK, Swain S, Patnaik UK, Behera M. Balloon mitral
valvuloplasty during pregnancy. Int J Gynaecol Obstet 2004; 85: 18-23.

Although certain protective measures were carried out
during the procedures in our study, including the use of
abdominal shield and the procedure being done only in
women over 20 weeks of gestation, there was still a further
need to investigate and follow-up the mothers and the infants
to identify any long term side effects of this procedure.
Our study is a small observation especially in terms of
long-term follow-up of patients who required PMV and longterm follow-up of their children. Though it is difficult to draw
conclusions due to the small sample size but our observation
shows that PMV is a relatively safe procedure, both for the
mother and the child even after a long-term follow-up like an
average of 4.5 years (234 weeks) in our study.
In summary, for pregnant patients who have severe
mitral stenosis and persistent heart failure along with
pulmonary hypertension, mitral valvuloplasty is a safe,
feasible and effective treatment with no obvious long-term
complications for both mother and foetus.2,5,7,18-21,24
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